Comparative Pharmacology
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus VIGPODER.
EXTENDED PHENYTOIN SODIUM vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
150 mg orally twice daily with or without food.
None Documented
None Documented
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category D/X
Category C
Anticonvulsant
Anticonvulsant